Document and Entity Information [Abstract] Document Information [Table] Entity Addresses, Address Type [Axis] Address Type [Domain] Former Address [Member] Former address Document Information [Line Items] Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials expenses. Accrued Clinical Trails Expenses, Current Accrued clinical trials expenses Employee-related Liabilities, Current Accrued compensation Other Accrued Liabilities, Current Other accrued expenses Total other accrued expenses Liabilities, Current Total current liabilities Convertible Notes Payable, Noncurrent Convertible notes at fair value, including related party amount of $1,755 and $34,600 at June 30, 2026 and December 31, 2025, respectively Operating Lease, Liability, Noncurrent Operating lease liability Noncurrent operating lease liability Derivative Liability, Noncurrent Derivative liability Warrants and Rights Outstanding Warrants liability at fair value Warrant liabilities The amount of contingent consideration liability as at the end of the reporting period. Contingent Consideration Liability Contingent consideration liability Other Liabilities, Noncurrent. Other liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 7) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' Deficit: Common Stock, Value, Issued Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, and 26,307,211 and 12,105,902 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Related Party [Member] Related Party Related Party Transaction [Line Items] Related Party Transactions Notes Payable, Noncurrent Convertible notes at fair value, related party amount Common Stock, Par or Stated Value Per Share Common stock, par value Common stock, par value per share Common Stock, Shares Authorized Common stock, shares authorized Number of shares of common stock authorized Common Stock, Shares, Issued Balance at ending (in shares) Balance at beginning (in shares) Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME Operating Expenses [Abstract] Operating expenses: Segment operating expenses: Selling, General and Administrative Expense Selling, general and administrative Research and Development Expense Research and development The amount of change in contingent consideration liability during the reporting period. Change In Amount Of Contingent Consideration Liability Change in fair value of contingent consideration Income related to the change in fair value of contingent consideration Operating Expenses Total operating costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other (loss) income: The amount of change in fair value of convertible notes. Change in Fair Value of Convertible Notes Change in fair value of convertible notes Change in fair value of convertible notes Fair Value Adjustment of Warrants Change in fair value of warrants Change in fair value of warrants Amount of gain (loss) recognized from issuance of warrants. Gain (Loss) from Issuance of Warrants Loss on issuance of warrants Loss on issuance of warrants Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Derivative, Loss on Derivative Loss on derivative liability Change in fair value of derivative liability Loss on derivative liability Other Nonoperating Income (Expense) Other income, net Nonoperating Income (Expense) Total other (loss) income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (Loss) income before taxes Net (loss) income Earnings Per Share, Basic Basic net (loss) income per share (in dollars per share) Net income (loss) per share, basic Earnings Per Share, Diluted Diluted net (loss) income per share (in dollars per share) Net income (loss) per share, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average shares of common stock outstanding used to compute basic net (loss) income per share Weighted average shares of common stock outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share Weighted average shares of common stock outstanding, diluted CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Statement [Line Items] CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statement Stockholders' Equity Attributable to Parent Balance at the ending Balance at the beginning Adjustments to Additional Paid in Capital, Warrant Issued Issuance of pre-funded warrants related to PIPE financing Residual value Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Issuance of shares and reclassification of liability related to cashless warrant exercises Warrants exercised Number of shares issued for warrants exercised during the current period. Stock Issued During Period, Shares, Warrants Exercised Issuance of shares and reclassification of liability related to cashless warrant exercises (in shares) Stock Issued During Period, Value, New Issues Issuance of shares related to at-the-market offering, net Stock Issued During Period, Shares, New Issues Issuance of shares related to at-the-market offering, net (in shares) Shares issued (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of shares related to exchange of convertible notes Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of shares related to exchange of convertible notes (in shares) Amount of increase to additional paid-in capital (APIC) for modification of cash-settled restricted stock unit under share-based payment arrangement. APIC, Share-Based Payment Arrangement, Cash Settled Restricted Stock Unit, Modification Modification of cash-settled restricted stock units APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to public offering. Public Offering [Member] Public offering 2026 Offering Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) in accrued expenses and other liabilities during the reporting period Increase Decrease In Accrued Expenses And Other Liabilities Accrued expenses and other liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Other assets and liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: The cash inflow from PIPE Financing Proceeds from PIPE Financing Proceeds from PIPE Financing Proceeds from Issuance of Common Stock Proceeds from issuance of at-the-market shares, net Proceeds from issuance of shares, net Proceeds from Issuance Initial Public Offering Proceeds from issuance of public offering shares, net Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: N/A Non-Cash Financing Activities [Abstract] Non-cash financing activities: Debt Conversion, Converted Instrument, Amount Settlement of convertible notes with common shares Principal amount of convertible promissory note Amount of derivative liability reclassified ti equity and warrant liabilities. Reclassification Of Derivative Liability To Equity And Warrant Liabilities Reclassification of derivative liability to equity and warrant liabilities in connection with PIPE financing Share-Based Payment Arrangement, Plan Modification, Incremental Cost Modification of cash-settled restricted stock units The fair value of warrants exercised in noncash financing activities. Warrants Exercised Cashless warrant exercises Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies No definition available. Public Offering The entire disclosure of public offering. Public Offering Disclosure [Text Block] Public Offering No definition available. Private Placement Financing The entire disclosure for information about private placement financing. Private Placement [Text Block] Private Placement Financing Daewoong Convertible Notes Convertible Debt [Table Text Block] Daewoong Convertible Notes Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Stockholders' Equity Note Disclosure [Text Block] Common Stock Share-based Compensation Share-Based Payment Arrangement [Text Block] Share-based Compensation Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policy for unaudited interim financial information. Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited Interim Financial Information Use of Estimates, Policy [Policy Text Block] Use of Estimates Segment Reporting, Policy [Policy Text Block] Segment Reporting Concentration Risk, Credit Risk, Policy [Policy Text Block] Risks and Uncertainties Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Disclosure of accounting policy for other accrued expenses. Other Accrued Expenses Policy [Policy Text Block] Other Accrued Expenses Debt, Policy [Policy Text Block] Convertible Notes Disclosure of accounting policy for contingent consideration. Contingent Consideration Policy [Policy Text Block] Contingent Consideration Derivatives, Policy [Policy Text Block] Derivative Liability Disclosure of accounting policy for Warrants. Warrants Policy [Policy Text Block] Warrants Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Lessee, Leases [Policy Text Block] Leases Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Earnings Per Share, Policy [Policy Text Block] Net (Loss) Income Per Share Commitments and Contingencies, Policy [Policy Text Block] Contingencies New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment reporting Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Schedule of Accrued Liabilities [Table Text Block] Schedule of other accrued expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net (loss) income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an anti-dilutive impact Fair Value Measurement Inputs and Valuation Techniques [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Represents information pertaining to Series A and B warrants. SeriesA And B Warrants [Member] Series A and B warrants Represents information pertaining to PIPE warrants and Daewoong warrants. PIPE Warrants and Daewoong Warrants [Member] PIPE Warrants and Daewoong Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurements Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Summary of significant inputs as of the valuation dates Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of activity for the Company's issued and outstanding warrants Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of recurring measurements for assets and liabilities at fair value The tabular disclosure of supplemental balance sheet information related to the operating lease. Lessee, Operating Lease, Supplemental Balance Sheet Information [Table Text Block] Schedule of supplemental balance sheet information related to the operating lease Lease, Cost [Table Text Block] Schedule of supplemental disclosures of operating cost and cash flow information related to operating leases The tabular disclosure of information pertaining to number of common shares reserved for future issuance. Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block] Schedule of common stock reserved for future issuance Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents the member information pertaining to ABP Sub Inc. 2019 Incentive Award Plan. ABP Sub Inc. 2019 Incentive Award Plan [Member] 2019 Incentive Award Plan Represents the member information pertaining to AEON Biopharma Inc 2023 Incentive Award Plan. AEON Biopharma Inc 2023 Incentive Award Plan 2023 Incentive Award Plan Represents the information pertaining to 2025 Employment Inducement Incentive Award Plan. Employment Inducement Incentive Award 2025 Plan [Member] 2025 Employment Inducement Incentive Award Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of restricted stock units activity Asset Acquisition [Table] Represents information pertaining to at-the-market offering. At The Market Offering [Member] At the market offering Private Placement [Member] Private Placement Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Daewoong. Daewoong [Member] Daewoong Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Represents the information pertaining to convertible notes maturing on March 2027. Convertible Notes Maturing On March 2027 [Member] Convertible Notes Maturing On March 2027 Represents the information pertaining to convertible notes maturing on April 2027. Convertible Notes Maturing On April 2027 [Member] Convertible Notes Maturing On April 2027 Convertible Debt [Member] Convertible Notes Represents information relates to new convertible note, issued in lie of exchange. New Convertible Note, Issued In Lie Of Exchange [Member] New Convertible Note, Issued In Lie Of Exchange Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to Exchange Agreement. Exchange Agreement [Member] Exchange Agreement Represents information relates to Daewong Warrant. Daewong Warrant [Member] Daewong Warrant Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Events Subsequent events Asset Acquisition [Line Items] Organization Stockholders' Equity Note, Stock Split, Conversion Ratio Split ratio Amount of aggregate number of common shares reserved for future issuance. Common Stock Capital Shares Reserved For Future Issuance, Amount Aggregate gross proceeds receivable under the plan The percentage of aggregate gross proceeds from sale of common stock to be paid as commission under the agreement. Percentage Of Gross Proceeds From Sale Of Common Stock To Be Paid As Commission Percentage of aggregate gross proceeds from sale of common stock Sale of Stock, Consideration Received on Transaction Net proceeds Proceeds from issuance of at-the-market shares, net Proceeds from Issuance or Sale of Equity Proceeds from issuance of shares, net Net proceeds Debt Instrument, Face Amount Principal amount Share Price Share price Debt Instrument, Convertible, Conversion Ratio Debt instrument ratio The maximum percentage of common stock beneficial ownership permitted under the agreement. Debt Instrument Convertible Beneficial Ownership Limitation Percentage Ownership limitation percentage Debt Conversion, Converted Instrument, Warrants or Options Issued Debt conversion amount Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price Exercise price per warrant Warrants and Rights Outstanding, Term Warrants expiration term Number of Operating Segments Number of operating segments Number of reportable segments not reported. Number Of Reportable Segments Not Disclosed Flag Number of reportable segments not reported Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Represents information pertaining to single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting Information [Line Items] Summary of Significant Accounting Policies Employee Benefits and Share-Based Compensation Compensation and benefits Professional Fees Professional and legal fees Expenses incurred for office and travel during the period. Office and Travel Expense Office and travel Amount of expense for selling, general and administrative and research and development. Selling, General and Administrative and Research and Development Expense Total selling, general and administrative, and research and development Other Nonoperating Income (Expense) [Abstract] Other segment items: Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Furniture and Fixtures [Member] Furniture and fixtures Equipment [Member] Equipment Leasehold Improvements [Member] Leasehold improvements Property, Plant and Equipment [Line Items] Property and Equipment Property, Plant and Equipment, Useful Life Useful life (in years) Property, Plant and Equipment, Gross Property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Amount of legal fee outstanding at the end of the period. Legal Fees Outstanding Legal expenses Sales and Excise Tax Payable, Current Excise tax liability Operating Lease, Liability, Current Less: Current portion (included in other accrued expenses) Operating lease liability - short term portion Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Carrying value of obligations incurred through that date and payable for supplies and analytical testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Payables For Supplies And Analytical Testing, Current Daewoong supplies & analytical testing Carrying value of obligations incurred through that date and payable for consulting fees pursuant to selling, general and administrative activities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Selling, General and Administrative Consulting Expenses, Current SG&A consulting expenses Carrying value of obligations incurred through that date and payable for consulting fees pursuant to research and development activities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Consulting Expenses, Current R&D consulting expenses The amount of current portion of other accrued liabilities. Remaining Other Accrued Liabilities Remaining other accrued expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Represents the information pertaining to Common stock options and restricted stock units. Common Stock Options and Restricted Stock Units [Member] Common stock options and restricted stock units Convertible Debt Securities [Member] Convertible notes Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an anti-dilutive impact Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an anti-dilutive impact Schedule of Stock by Class [Table] Represents information pertaining to series warrants. Series Warrants [Member] Series Warrants Represents information pertaining to Series A warrants. SeriesA Warrants [Member] Series A Represents information pertaining to Series B warrants. Series B Warrants [Member] Series B Class of Stock [Line Items] Public Offering The number of common units issued during period. Number Of Common Units Issued During Period Number of common units The number of common shares issuable per common unit. Number Of Common Shares Issuable Per Common Unit Number of common shares issuable per common unit The number of warrants issuable per common unit. Number of Warrants Issuable Per Common Unit Number of warrants issuable per common unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of common stock per warrant Represents floor price of warrants before stockholder approval date. Floor Price of Warrants Before Stockholder Approval Date Floor price of warrants before stockholder approval date Represents floor price of warrants after stockholder approval date. Floor Price of Warrants After Stockholder Approval Date Floor price of warrants after stockholder approval date. The number of days to purchase additional shares. Number Of Days Option To Purchase Additional Shares Number of days to purchase additional shares The maximum percentage of common stock that can be purchased using the option. Maximum Percentage of Common Shares to be Purchased in the Option Maximum percentage of common stock using option The purchase price of additional warrant. Purchase Price of Additional Warrant Purchase Price The number of warrants exercised during the period. Class of Warrant or Right, Number of Warrants Exercised Number of warrants exercised Represents the multiplier used to determine the number of shares issued when the holder of warrants opts for an alternative cashless exercise. Warrants Multiplier Factor Warrants multiplier factor Number of warrants exercised. Class of Warrant or Right, Exercised Number of warrants exercised Warrants exercised Class of Warrant or Right, Outstanding Balance at the end of the period Balance at the beginning of the period Warrants outstanding Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Represents information pertaining to pipe pre-funded warrants. PIPE Pre-Funded Warrants [Member] PIPE pre-funded warrants Represents information pertaining to pipe warrants. Pipe Warrants [Member] Pipe Warrants Represents information pertaining to true-up warrants. True-Up Warrants [Member] True-up warrants Subsidiary, Sale of Stock [Line Items] Private Placement Financing Shares Issued, Price Per Share Original issue price Price per warrant issued in lieu of a common shares under stock transaction. Price Per Warrant Issued Warrant price Period during which the investor has the right to participate in the future financing by the company, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Stock Transaction, Investor Protection Period Investor protection period Represents minimum floor price for exercising the warrants. Minimum Floor Price For Exercising Warrants Minimum floor price for exercising warrants Amount of unrealized gain (loss) on derivatives at the date of issuance. Unrealized Gain (Loss) On Initial Recognition Of Derivatives Loss on derivatives at initial recognition Fair value of warrants on the grant date. Warrants And Rights, Grant Date Fair Value Grant date fair values for warrants Schedule of Long-Term Debt Instruments [Table] Represents the information pertaining to subscription agreement. Subscription Agreement [Member] Subscription Agreement Represents the information pertaining to Amended Convertible Promissory Note Purchase Agreement. Amended Convertible Promissory Note Purchase Agreement [Member] Amended convertible promissory note purchase agreement Represents information pertaining to pre-funded warrants. Pre Funded Warrants [Member] Pre Funded Warrants Debt Instrument [Line Items] Represents the principal amount of debt issuable as per the agreement. Debt Instrument, Principal Amount of Debt Issuable Principal amount of debt issuable Debt Instrument, Interest Rate During Period Annual rate of interest (as a percent) Represents the term for issuance of convertible note following the compliance with certain conditions. Debt Instrument, Number Of Convertible Notes Issued Number of convertible note sold The amount of income (expense) related to decrease (increase) in fair value of Convertible Notes. Income (expense) Related to Decrease (Increase) in Fair Value of Convertible Notes Expense related to increase in fair value Long-Term Debt Principal amount outstanding Convertible Debt, Fair Value Disclosures. Estimated fair value of convertible notes Estimated fair value of convertible notes Represents the number of warrants issued. Class Of Warrant Or Right, Number Of Warrants Issued Number of warrants issued Debt Conversion, Converted Instrument, Shares Issued Number of shares issued upon conversion Represents the minimum aggregate gross cash proceeds required from a bona fide third party financing to trigger automatic conversion of the New Convertible Note. Qualified Financing Minimum Proceeds Threshold Qualified financing minimum proceeds threshold Represents the information written on notice period for the third party. Written On Notice Period For Third Party Written on notice period for third party Number of trading days used to calculate the volume weighted average price of common stock for determining the conversion price of the New Convertible Note under the Optional Conversion provision. Conversion Price Look back Period Trading Days Conversion price look back period trading days Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Represents information relates to Pre-funded Warrant. Pre-funded Warrant [Member] Pre-funded Warrant Debt Instrument, Measurement Input Convertible notes, measurement input Debt Conversion, Original Debt, Amount Debt conversion, original debt Class of Stock [Axis] Class of Stock [Domain] Represents the information pertaining to founder shares. Founder Shares. [Member] Founder Shares Represents the information pertaining to Migraine Phase 3 Contingent Founder Shares. Migraine Phase 3 Contingent Founder Shares [Member] Migraine Phase 3 Contingent Founder Shares Represents the information pertaining to CD BLA Contingent Founder Shares. CD BLA Contingent Founder Shares [Member] CD BLA Contingent Founder Shares Represents the information pertaining to Episodic/Chronic Migraine Contingent Founder Shares. Episodic/Chronic Migraine Contingent Founder Shares [Member] Episodic/Chronic Migraine Contingent Founder Shares Represents the information pertaining to Episodic Migraine Contingent Consideration Shares. Episodic Migraine Contingent Consideration Shares [Member] Episodic Migraine Contingent Consideration Shares Represents the information pertaining to Chronic Migraine Contingent Consideration Shares. Chronic Migraine Contingent Consideration Shares [Member] Chronic Migraine Contingent Consideration Shares Represents information pertaining to old aeon common stock. Old AEON Common Stock [Member] Old AEON Common Stock Vesting [Axis] Vesting [Domain] Represents the tranche of vesting, upon the achievement of the conditions for the issuance of the CD BLA Contingent Consideration Shares on or prior to the CD BLA Outside Date. Upon The Achievement Of The Conditions For The Issuance Of The CD BLA Contingent Consideration Shares On Or Prior To The CD BLA Outside Date [Member] Upon the achievement of the conditions for the issuance of the CD BLA Contingent Consideration Shares on or prior to the CD BLA Outside Date Legal Entity [Axis] Entity [Domain] Represents the information pertaining to Priveterra. Priveterra Priveterra Represents the number of additional shares to be issued. Number Of Additional Shares To Be Issued Number of additional shares to be issued Represents the percentage of shares are unvested and subject to the restrictions and forfeiture provisions Percentage of Shares Unvested And Subject To The Restrictions And Forfeiture Provisions Percentage of shares unvested and subject to the restrictions and forfeiture provisions Number of founder shares subject to vesting and forfeiture conditions. Number of Founder Shares Subject to Vesting and Forfeiture Number of founder shares subject to vesting and forfeiture conditions The number of founder shares forfeited during the period as a result of vesting event not occurring. Number Of Founder Shares Subject To Vesting Forfeited Number of founder shares forfeited Represents the percentage of shares are not subject to restrictions and forfeiture provisions. Percentage of Shares Not Subject to Restrictions And Forfeiture Provisions Percentage of shares not subject to restrictions and forfeiture provisions Threshold increase in number of Episodic Migraine Contingent Consideration Shares in the in the event the satisfaction of the conditions for the issuance of the Episodic Migraine Contingent Consideration Shares occurs prior to the satisfaction of the conditions for the issuance of the Chronic Migraine Contingent Consideration Shares. Threshold Increase in Episodic Migraine Contingent Consideration Shares Threshold increase in Episodic Migraine Contingent Consideration Shares The number of Chronic Migraine Contingent Consideration Shares by increase in Episodic Migraine Contingent Consideration Shares. Number of Chronic Migraine Contingent Consideration Shares by Increase in Episodic Migraine Contingent Consideration Shares Number of Chronic Migraine Contingent Consideration Shares by increase in Episodic Migraine Contingent Consideration Shares The number of Contingent Consideration Shares to be issued upon Threshold Increase in Episodic Migraine Contingent Consideration Shares. Number of Contingent Consideration Shares to be Issued Upon Threshold Increase in Episodic Migraine Contingent Consideration Shares Number of Contingent Consideration Shares to be issued upon Threshold Increase in Episodic Migraine Contingent Consideration Shares Represents the number of common shares become due and payable if product is licensed before satisfaction of issuance of contingent consideration shares. Number of Shares Become Due and Payable if Product Licenses given before Satisfaction of Issuance of Contingent Shares Number of common shares become due and payable Represents the reduction in Episodic Migraine Contingent Consideration Shares if product is licensed before satisfaction of issuance of contingent consideration shares. Reduction in Number of Episodic Migraine Contingent Consideration Shares if Product Licenses given before Satisfaction of Issuance of Shares Reduction in Episodic Migraine Contingent Consideration Shares Represents the reduction in Episodic Migraine Contingent Consideration Shares if product is licensed before satisfaction of issuance of contingent consideration shares. Reduction in Number of Chronic Migraine Contingent Consideration Shares if Product Licenses given before Satisfaction of Issuance of Shares Reduction in number of Chronic Migraine Contingent Consideration Shares Represents the minimum number of Chronic Migraine Contingent Consideration Shares after reduction if product is licensed before satisfaction of issuance of contingent consideration shares. Minimum Number of Chronic Migraine Contingent Consideration Shares after Reduction Minimum number of Chronic Migraine Contingent Consideration Shares after Reduction Ratio at which one class of shares converts into another in a transaction. Share Conversion Ratio Conversion of Stock, Shares Issued Number of common stock issued on conversion Maximum number of common shares issuable as contingent consideration in connection with a business combination, subject to the satisfaction of specified conditions or performance targets. Maximum Contingent Consideration Shares Issuable Maximum contingent consideration shares issuable Class of Warrant or Right [Table] Represents information pertaining to private placement warrants. Private Placement Warrants [Member] Private placement warrants Represents information pertaining to SPAC warrants. SPAC Warrants [Member] SPAC Warrants Represents information pertaining to Odean warrants. Odean Warrants [Member] Odean Warrants Class of Warrant or Right [Line Items] Fair Value Measurements Amount of cash payable to settle the litigation against the company. Litigation Settlement, Cash Litigation settlement cash Amount of shares issuable to settle the litigation against the company. Litigation Settlement, Share Litigation settlement share Number of warrants issuable to settle the litigation against the company. Litigation Settlement, Warrants Issued Litigation settlement warrants issued Litigation Settlement, Gain Litigation settlement gain Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Share Price [Member] Stock Price Measurement Input, Exercise Price [Member] Exercise Price Measurement Input, Price Volatility [Member] Expected volatility Measurement Input, Risk Free Interest Rate [Member] Risk-free interest rate Measurement Input, Expected Term [Member] Expected life (in years) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Level 3 Warrants and Rights Outstanding, Measurement Input Warrants, measurement input Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Measurements Liability Class [Axis] Fair Value by Liability Class [Domain] Represents information pertaining to warrant liabilities. Warrant Liabilities [Member] Warrant Liabilities Represents the information pertaining to Contingent consideration. Contingent Consideration [Member] Contingent consideration Derivative Financial Instruments, Liabilities [Member] Derivative Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Recurring measurements for assets and liabilities at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at the end Balance at the beginning Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Issuance of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Amount of exchange of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Exchanges Exchange of convertible notes Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Settlement of derivative liability Amount of cashless exercises of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Cashless Exercise Warrant cashless exercise Lessee, Operating Lease, Term of Contract Term of operating leases Lessee, Operating Lease, Renewal Term Renewal term Assets and Liabilities, Lessee [Abstract] Supplemental balance sheet information related to the operating lease Lessee, Operating Lease, Liability, to be Paid [Abstract] Minimum lease payments by fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2026 Lessee, Operating Lease, Liability, to be Paid, Year One 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three 2029 Lessee, Operating Lease, Liability, to be Paid Total future minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Operating Lease, Liability Present value of lease payments Lessee, Operating Lease, Remaining Lease Term Remaining lease term in years Lessee, Operating Lease, Discount Rate Discount rate Operating Lease, Cost Cost of operating leases Operating Lease, Payments Cash paid for operating leases Collaborative Arrangement and Arrangement Other than Collaborative [Table] Daewoong License and Supply Agreement Daewoong License and Supply Agreement [Member] Daewoong License and Supply Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Commitments and Contingencies Represents the automatic renewal for unlimited additional term. Automatic Renewal For Unlimited Additional Term Automatic renewal for unlimited additional term Represents the termination upon a continuing default term. Termination Upon Continuing Default Term Termination upon a continuing default term Represents the termination upon a payment default term. Termination Upon Payment Default Term Termination upon a payment default term Ownership percentage threshold of common stock (including affiliates and shares issuable upon conversion of the New Convertible Note) that, if sold by Daewoong, results in the termination and expiration of the Termination Purchase Right. Termination Purchase Right Ownership Threshold Percentage Termination purchases right ownership threshold percentage Represents the price of know how in the event of termination. Price Of Know How In The Event Of Termination Price of know how in the event of termination Represents information pertaining to Employee Stock Purchase Plan 2023. Employee Stock Purchase Plan 2023 [Member] 2023 Employee Stock Purchase Plan Dividends, Common Stock, Cash Amount of cash dividend has been declared Common Stock, Voting Rights Number of votes per share Common Stock, Capital Shares Reserved for Future Issuance Number of additional shares to be issued Total common stock reserved Common stock reserved The threshold percentage of total number of shares issued and outstanding as a part increase in share issuance. Threshold Percentage Of Total Number Of Shares Issued And Outstanding Number of shares issued and outstanding (in %) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Aggregate number of shares available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Issued shares Stock options Restricted Stock Units (RSUs) [Member] RSU Number of common shares reserved for future issuance for share based compensation. Common Stock, Capital Shares Reserved for Future Issuance, Share Based Compensation Stock options issued and outstanding Number of common shares reserved for future issuance for stock incentive plan. Common Stock, Capital Shares Reserved for Future Issuance, Stock Incentive Plan Restricted stock units (unvested) Number of common shares reserved for future issuance for stock incentive plan and employee stock purchase plan. Common Stock, Capital Shares Reserved for Future Issuance, Stock Incentive Plan And Employee Stock Purchase Plan Shares available for future issuance under the stock incentive plans and employee stock purchase plan Number of common shares reserved for future issuance for warrants. Common Stock, Capital Shares Reserved for Future Issuance, Warrants Warrants Number of common shares reserved for future issuance for contingent consideration. Common Stock, Capital Shares Reserved for Future Issuance, Contingent Consideration Contingent consideration Number of common shares reserved for future issuance for convertible debt securities. Common Stock, Capital Shares Reserved for Future Issuance, Convertible Debt Securities Convertible notes Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Options, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, end of period Outstanding, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable, end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, end of period Outstanding, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable, end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual life of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual life of options exercisable Share-Based Payment Arrangement, Expense Share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation expense related to non-vested stock options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average remaining requisite service period for which unrecognized compensation expense Represents the information related to earnout vesting. Earnout Vesting [Member] Earnout Vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Other than options, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding, ending of period Outstanding, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Other than options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Outstanding, ending of period Outstanding, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Amount of expense for award under share-based payment arrangement with earnout vesting criteria. Excludes amount capitalized. Share-Based Payment Arrangement, Earnout vesting, Expense Share-based compensation expense related Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense related to other than options Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Number of additional shares authorized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] Selling, General and Administrative Expenses [Member] Selling, general and administrative expenses Research and Development Expense [Member] Research and development expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions Amount of increase to additional paid-in capital resulting from the reclassification of accrued compensation in connection with the conversion of restricted stock units. Increase in Additional Paid-in Capital from Reclassification of Accrued Compensation for Converted Restricted Stock Units Increase in additional paid-in capital from reclassification of accrued compensation for converted restricted stock units Subsequent Event [Table] Over-Allotment Option [Member] Over-Allotment Represents information relates to two-year milestone pre fund warrant. Two-Year Milestone Warrant [Member] Two-Year Milestone Warrant Represents information relates to five-year milestone pre fund warrant. Five-Year Milestone Warrant [Member] Five-Year Milestone Warrant Subsequent Event [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Represents the number of warrants per each share. Number of Warrants per Each Share Number of warrants per common stock Public Offering price per common share and accompanying milestone warrants. Offering Price per Common Share and Accompanying Milestone Warrants Public offering price per common stock and accompanying milestone warrants Offering Price per pre-funded warrant and accompanying milestone warrants. Offering Price Per Warrants Issued Public offering price per warrants issued Offering Price per pre-funded warrant and accompanying milestone warrants. Warrants Reserved for Future Issuance Number of warrants to be issued Represents the aggregate fixed lease payments excluding common area maintenance charges, taxes, insurance, and other variable payments under operating lease. Lessee, Operating Lease, Aggregate Fixed Lease Payments Aggregate fixed lease payments